Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UBT251 DDI Study in Overweight or Obese Participants
NCT07785934Phase 1Recruiting
- Start
- May 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UBT251 in obesity and Overweight. Primary endpoint: Area under plasma concentration-time curve at 168 hours. Started May 2026; status: recruiting.
02
Drugs
UBT251
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07785934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07785934.